Novo Nordisk 's ( NVO +2.93%) shareholders must be happy to see 2025 finally come to a close. It was not a good year for the ...

With just about a week to go until 2026, Novo announced that its new weight loss pill under the brand name Wegovy had been ...

Novo Nordisk has had a difficult year: a tumbling stock price resulting in the biggest leadership shakeup in the company's ...

The U.S. Food and Drug Administration has approved Novo Nordisk’s Wegovy® pill, making it the first and only oral GLP-1 ...

Novo Nordisk plans to sell its newly approved obesity pill directly to patients at a lower price than a competing medicine ...

Novo Nordisk has been handed a crucial legal win by China's Supreme Court, which has upheld the company's patent protection ...

Novo Nordisk gained a head start in the GLP-1 race but then fell behind; Pfizer is working hard to catch up to the new leader ...

The pharmaceutical giant's stock has tumbled over the past year and a half, but it could be poised to storm back.

The U.S. Food and Drug Administration on Dec. 22 approved a pill version of Novo Nordisk’s weight-loss drug Wegovy.

The FDA has approved the oral version of Novo Nordisk’s injectable weight loss drug Wegovy, making it the first GLP-1 pill to ...

Omeros transitions from a distressed microcap to a small-cap following a transformative Novo Nordisk deal and FDA approval of ...

Monday’s approval gives Novo Nordisk a win against GLP-1 competitor Eli Lilly, which manufactures a weight loss injectable ...